Trial Profile
Plasma and intrapulmonary population pharmacokinetics of piperacillin/tazobactam in critically ill patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Jul 2019
Price :
$35
*
At a glance
- Drugs Piperacillin/tazobactam (Primary)
- Indications Bacterial infections; Nosocomial pneumonia
- Focus Pharmacokinetics
- Acronyms PROPEL
- 11 Jul 2019 Status changed from active, no longer recruiting to completed.
- 17 Oct 2013 Accrual to date is 100% according to United Kingdom Clinical Research Network record.
- 17 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.